Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus [*]

 

 Buy Article Permissions and Reprints

Introduction

Vildagliptin is a potent and selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which enhances endogenous glucagon-like peptide-1 (GLP-1) levels and improves islet function by increasing both α- and β-cell responsiveness to glucose [1] [2]. Vildagliptin produced statistically significant and clinically meaningful reductions in HbA1c values when given as monotherapy in drug-naïve patients [3] [4] or in combination with metformin [5] and pioglitazone [6], without weight gain and with minimal hypoglycemia. In patients with a long history of diabetes requiring insulin therapy, a population notoriously difficult to treat because therapeutic options are limited, the addition of vildagliptin to insulin therapy was associated with improved glycemic control and less hypoglycemia after six months of treatment [7].

The present study represents a report of longer-term data from this recently reported clinical trial, undertaken to assess the efficacy and safety of vildagliptin therapy over one year in patients with long-standing type 2 diabetes mellitus (T2DM) that was inadequately controlled by insulin therapy.

1 The trial (NCT00138606) described here is registered with ClinicalTrials.gov.

References

• 1 Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. J Clin Endocrinol Metab. 2004;  89 2078-2084
  CrossrefPubMed
• 2 Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. J Clin Endocrinol Metab. 2005;  90 4888-4894
  CrossrefPubMed
• 3 Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Diabetes Res Clin Pract. 2007;  76 132-138
  CrossrefPubMed
• 4 Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Diabetes Care. 2007;  30 217-223
  CrossrefPubMed
• 5 Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Diabetes Care. 2007;  30 890-895
  CrossrefPubMed
• 6 Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Diabetes Obes Metab. 2007;  9 166-174
  CrossrefPubMed
• 7 Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Diabetologia. 2007;  50 1148-1155
  CrossrefPubMed
• 8 Henderson JN, Allen KV, Deary IJ, Frier BM. Diabetes Med. 2003;  20 1016-1021
  CrossrefPubMed
• 9 Meneilly GS, Cheung E, Tuokko H. Diabetes. 1994;  43 403-410
  PubMed
• 10 Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Diabetes Care. 1997;  20 135-141
  CrossrefPubMed
• 11 Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, Fronzo RA. J Clin Endocrinol Metab. 2007;  92 1249-1255
  CrossrefPubMed
• 12 Dunning BE, Foley JE, Ahren B. Diabetologia. 2005;  48 1700-1713
  CrossrefPubMed
• 13 Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, Basu A, Vittone JL, Klee GG, Arora P, Jensen MD, Toffolo G, Cobelli C, Rizza RA. Diabetes. 2003;  52 1738-1748
  PubMed

1 The trial (NCT00138606) described here is registered with ClinicalTrials.gov.

Correspondence

V. FonsecaMD 

Endocrinology Department

Tulane University Health Sciences Center

1430 Tulane Avenue - SL 53

New Orleans

70112 Louisiana

USA

Phone: +1/504/988 40 26

Fax: +1/504/988 62 71

Email: vfonseca@tulane.edu